Intest Res Search

CLOSE


Original article

  • HOME
  • ARTICLE CATEGORY
  • Original article
Clinical presentation of COVID-19 in patients with inflammatory bowel disease: a systematic review and meta-analysis
Anupam K. Singh, Anuraag Jena, Praveen Kumar-M, Daya Krishna Jha, Vishal Sharma
Intest Res. 2022;20(1):134-143.   Published online January 18, 2021
Full text    PubReader    ePub    Crossref - TDM    PDF    Supplementary Material
Close layer
prev next
An evaluation of dietary adequacy among patients with constipation-predominant irritable bowel syndrome in Malaysia
Nor Hamizah Shafiee, Nurul Huda Razalli, Norfilza M. Mokhtar, Eunice Tan, Raja Affendi Raja Ali
Intest Res. 2022;20(1):124-133.   Published online January 22, 2021
Full text    PubReader    ePub    Crossref - TDM    PDF    
Close layer
prev next
Incidence comparison of adverse events in patients with inflammatory bowel disease receiving different biologic agents: retrospective long-term evaluation
Brigida Barberio, Edoardo Vincenzo Savarino, Timothy Card, Cristina Canova, Francesco Baldisser, Alessandro Gubbiotti, Davide Massimi, Matteo Ghisa, Fabiana Zingone
Intest Res. 2022;20(1):114-123.   Published online August 4, 2021
Full text    PubReader    ePub    Crossref - TDM    PDF    Supplementary Material
Close layer
prev next
Biomarker dynamics during infliximab salvage for acute severe ulcerative colitis: C-reactive protein (CRP)-lymphocyte ratio and CRP-albumin ratio are useful in predicting colectomy
Danny Con, Bridgette Andrew, Steven Nicolaides, Daniel R van Langenberg, Abhinav Vasudevan
Intest Res. 2022;20(1):101-113.   Published online March 12, 2021
Full text    PubReader    ePub    Crossref - TDM    PDF    Supplementary Material
Close layer
prev next
Long-term efficacy and tolerability of dose-adjusted thiopurine treatment in maintaining remission in inflammatory bowel disease patients with NUDT15 heterozygosity
Takato Maeda, Hirotake Sakuraba, Hiroto Hiraga, Shukuko Yoshida, Yoichi Kakuta, Hidezumi Kikuchi, Shogo Kawaguchi, Keisuke Hasui, Tetsuya Tatsuta, Daisuke Chinda, Tatsuya Mikami, Shinsaku Fukuda
Intest Res. 2022;20(1):90-100.   Published online January 22, 2021
Full text    PubReader    ePub    Crossref - TDM    PDF    Supplementary MaterialGraphic abstract
Close layer
prev next
Effectiveness of administering zinc acetate hydrate to patients with inflammatory bowel disease and zinc deficiency: a retrospective observational two-center study
Kensuke Sakurai, Shigeru Furukawa, Takehiko Katsurada, Shinsuke Otagiri, Kana Yamanashi, Kazunori Nagashima, Reizo Onishi, Keiji Yagisawa, Haruto Nishimura, Takahiro Ito, Atsuo Maemoto, Naoya Sakamoto
Intest Res. 2022;20(1):78-89.   Published online January 22, 2021
Full text    PubReader    ePub    Crossref - TDM    PDF    Supplementary Material
Close layer
prev next
Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study
Vitaliy Y. Poylin, Jose Cataneo Serrato, Jonathan Pastrana Del Valle, Joseph D. Feuerstein
Intest Res. 2022;20(1):72-77.   Published online February 3, 2021
Full text    PubReader    ePub    Crossref - TDM    PDF    
Close layer
prev next
Maintaining infliximab induced clinical remission with azathioprine and 5-aminosalicylates in acute severe steroid-refractory ulcerative colitis has lower cost and high efficacy (MIRACLE): a multicenter study
Ramit Mahajan, Arshdeep Singh, Saurabh Kedia, Kirandeep Kaur, Vandana Midha, Pabitra Sahu, Varun Mehta, Dharmatma Singh, Namita Bansal, Khushdeep Dharni, Sandeep Kaushal, Vineet Ahuja, Ajit Sood
Intest Res. 2022;20(1):64-71.   Published online February 3, 2021
Full text    PubReader    ePub    Crossref - TDM    PDF    
Close layer
prev next
The dietary practices and beliefs of British South Asian people living with inflammatory bowel disease: a multicenter study from the United Kingdom
Benjamin Crooks, Ravi Misra, Naila Arebi, Klaartje Kok, Matthew J. Brookes, John McLaughlin, Jimmy K. Limdi
Intest Res. 2022;20(1):53-63.   Published online January 6, 2021
Full text    PubReader    ePub    Crossref - TDM    PDF    Supplementary Material
Close layer
prev next
Inflammatory Bowel Diseases
Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?
Eirini Theodoraki, Eleni Orfanoudaki, Kalliopi Foteinogiannopoulou, Evangelia Legaki, Maria Gazouli, Ioannis E. Koutroubakis
Intest Res. 2021;19(4):461-467.   Published online August 18, 2020
Full text    PubReader    ePub    Crossref - TDM    PDF    
Close layer
prev next
Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis
Taku Kobayashi, Hiroaki Ito, Toshifumi Ashida, Tadashi Yokoyama, Masakazu Nagahori, Tomoki Inaba, Mitsuhiro Shikamura, Takayoshi Yamaguchi, Tetsuharu Hori, Philippe Pinton, Mamoru Watanabe, Toshifumi Hibi
Intest Res. 2021;19(4):448-460.   Published online August 18, 2020
Full text    PubReader    ePub    Crossref - TDM    PDF    Supplementary Material
Close layer
prev next
High mucosal cytomegalovirus DNA helps predict adverse short-term outcome in acute severe ulcerative colitis
Saransh Jain, Divya Namdeo, Pabitra Sahu, Saurabh Kedia, Peush Sahni, Prasenjit Das, Raju Sharma, Vipin Gupta, Govind Makharia, Lalit Dar, Simon PL Travis, Vineet Ahuja
Intest Res. 2021;19(4):438-447.   Published online November 6, 2020
Full text    PubReader    ePub    Crossref - TDM    PDF    Supplementary Material
Close layer
prev next
Clinical characteristics of inflammatory bowel disease patients with immunoglobulin A nephropathy
Ryohei Hayashi, Yoshitaka Ueno, Shinji Tanaka, Kana Onishi, Takeshi Takasago, Masaki Wakai, Toshikatsu Naito, Kensuke Sasaki, Shigehiro Doi, Takao Masaki, Kazuaki Chayama
Intest Res. 2021;19(4):430-437.   Published online November 9, 2020
Full text    PubReader    ePub    Crossref - TDM    PDF    Graphic abstract
Close layer
prev next
Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study
Haruhiko Ogata, Takashi Hagiwara, Takeshi Kawaberi, Mariko Kobayashi, Toshifumi Hibi
Intest Res. 2021;19(4):419-429.   Published online November 10, 2020
Full text    PubReader    ePub    Crossref - TDM    PDF    
Close layer
prev next
Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn’s disease: 3-year results from a real-world study
Tadakazu Hisamatsu, Yasuo Suzuki, Mariko Kobayashi, Takashi Hagiwara, Takeshi Kawaberi, Haruhiko Ogata, Toshiyuki Matsui, Mamoru Watanabe, Toshifumi Hibi
Intest Res. 2021;19(4):408-418.   Published online November 20, 2020
Full text    PubReader    ePub    Crossref - TDM    PDF    
Close layer
prev next
  • SCImago Journal & Country Rank
  • AOCC 2018
  • CSIBD
  • JSIBD
  • kasid
  • TSIBD
  • CCF
  • PubMed Central
  • PubMed
  • KoreaMed
  • KoMCI
  • Scopus
  • Directory of Open Access Journals (DOAJ)
  • GoogleScholar
  • EBSCO
  • Similarity Check
  • Crossref Cited-by Linking
  • CrossMark
  • Funder Registry
  • ORCID
  • COPE
  • KOFST
  • TrendMD

ABOUT
ARTICLE & TOPICS
Article Category

Browse all articles >

TOPICS

Browse all articles >

BROWSE ARTICLES
EDITORIAL POLICY
AUTHOR INFORMATION
Editorial Office
Room 305, Lotte Gold Rose II, 31 Seolleung-ro 86-gil, Gangnam-gu, Seoul 06193, Korea
Tel: +82-2-957-6145    Fax: +82-2-957-6146    E-mail: thekasid@irjournal.org                

Copyright © 2022 by Korean Association for the Study of Intestinal Diseases.

Developed in M2PI

Close layer
prev next